Zhongke Xinsheng, a leading multi-omics company in mass spectrometry, completed hundreds of millions of yuan in Series B financing

Recently, Zhongke New Life, which focuses on the application of mass spectrometry and multi-omics precision medicine, announced that it has completed hundreds of millions of yuan in Series B financing.

Founded in July 2004, Zhongke New Life is a high-tech enterprise invested and established by the former Shanghai Institute of Biological Sciences, Chinese Academy of Sciences.

The company's comprehensively built laboratory for analytical method development, testing, and production of intelligent drugs strictly abides by CMA, CNAS and GMP standards, escorting "biological and innovative drug research and development, compliant development and production, and integrated registration".

With the help of this round of capital, the company will continue to deepen its efforts in the field of big health, adhering to the corporate values ​​of "innovation-oriented, integrity-first, and pragmatism-oriented", accelerating the expansion and upgrading of technology platforms, the research and development of innovative precision medical products, The expansion of global marketing channels and the introduction of high-end talents will enhance the advantages of Zhongke New Life in the field of mass spectrometry multi-omics, become a leader in data-driven multi-omics technology in clinical translation and innovative pharmaceutical research and development, and promote precision medicine in China.

About Legend Capital

Founded in 2001, Legend Capital is a professional investment institution focusing on early-stage venture capital and growth-stage investment

About Haoyue Capital

Haoyue Capital, founded in January 2014, is China's leading industrial investment bank focusing on the medical and health industry